AEON Biopharma stock analysis
Want to see AEON full AI Analyst Report?
AEON Biopharma (AEON) Stock Price & Analysis
AEON Stock Chart & Stats
- Day’s Range
- $0.15 - $0.17
- 52-Week Range
- $0.13 - $1.45
- Previous Close
- $0.16
- Volume
- N/A
- Average Volume (3M)
- 1.06M
- Market Cap
- $9.04M
- Enterprise Value
- $35.69M
- Total Cash (Recent Filing)
- $3.43M
- Total Debt (Recent Filing)
- $2.77M
- Price to Earnings (P/E)
- ―
- Beta
- 1.55
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
ABP-450 Regulatory Pathway
The FDA’s agreement in principle provides a defined development route for ABP-450 and may reduce the need for a standalone comparative efficacy study. If execution is successful, the streamlined evidence package could improve development efficiency and advance the candidate toward a 2027 BLA filing.
Extended Financial Runway
Additional financing and restored exchange compliance give AEON more time to execute its ABP-450 development plan without an immediate funding interruption. The extended runway supports planned regulatory and clinical activities, although future progress remains dependent on continued access to capital.
Improving Cash-Burn Trend
Although AEON continues to consume cash, the narrowing outflow indicates some improvement in financial efficiency compared with prior periods. If maintained, lower burn could extend the company’s available funding horizon and allow more of its capital to support the ABP-450 program.
Bears Say
Pre-Revenue Operating Model
AEON has not yet established recurring commercial revenue and continues to absorb substantial development costs. This leaves the company without operating leverage from product sales, makes progress dependent on regulatory success, and increases the importance of future financing or partnership support.
Negative Equity And Small Asset Base
Persistent negative equity and a small asset base indicate constrained balance-sheet strength and limited financial flexibility. This weakens the company’s ability to absorb setbacks, fund development internally, or negotiate from a position of strength, while volatile debt levels add to capital-structure uncertainty.
Ongoing External Funding Dependence
Sustained negative operating and free cash flow means AEON cannot currently finance its activities through internally generated cash. Continued development therefore depends on additional capital or strategic transactions, creating funding risk and potential dilution before commercial products generate revenue.
AEON Biopharma News
Aeon submits IND application to the FDA for comparative pharmacodynamic study
Aeon Biopharma (AEON) announced the submission of an investigational new drug, or IND, application to the FDA for a comparative pharmacodynamic study utilizing compound muscle action potential measurements. The submission
Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450
AEON Biopharma (AEON) announced receipt of the official minutes from its Biosimilar Biological Product Development Type 2b meeting held with the U.S. Food and Drug Administration regarding ABP-450’s development pathway.
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
What is AEON Biopharma’s market cap?
When is AEON Biopharma’s upcoming earnings report date?
How were AEON Biopharma’s earnings last quarter?
Is AEON Biopharma overvalued?
Does AEON Biopharma pay dividends?
What is AEON Biopharma’s EPS estimate?
How many shares outstanding does AEON Biopharma have?
What happened to AEON Biopharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of AEON Biopharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
AEON Biopharma
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Bancroft
- Employees
- 8
- Website
- www.aeonbiopharma.com
- Address
- 5 Park Plaza, Irvine, CA, 92614, US
AEON Biopharma (AEON) Earnings & Revenues
AEON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |












